Vericel Corp  

(Public, NASDAQ:VCEL)   Watch this stock  
Find more results for NASDAQ:ASTM
3.21
+0.03 (0.94%)
Real-time:   11:00AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.16 - 3.21
52 week 2.55 - 4.35
Open 3.18
Vol / Avg. 1,371.00/38,456.00
Mkt cap 76.36M
P/E     -
Div/yield     -
EPS -1.42
Shares 23.79M
Beta 1.04
Inst. own 53%
Aug 12, 2015
Q2 2015 Vericel Corp Earnings Call - Webcast
Aug 12, 2015
Q2 2015 Vericel Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -15.84% -69.18%
Operating margin -16.67% -81.73%
EBITD margin - -62.28%
Return on average assets -20.14% -70.15%
Return on average equity - -
Employees 190 -
CDP Score - -

Address

64 Sidney St
CAMBRIDGE, MA 02139-4170
United States - Map
+1-734-9305555 (Phone)
+1-734-6650485 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Vericel Corporation (Vericel), formerly Aastrom Biosciences, Inc. develops patient-specific expanded cellular therapies for use in the treatment of patients with diseases and conditions. Vericel markets two autologous cell therapy products in the United States: Carticel (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee, and Epicel (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns greater than or equal to 30% of total body surface area (TBSA). The Company is also developing ixmyelocel-T, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. The Company has two cell manufacturing facilities in Cambridge, Massachusetts and Copenhagen, Denmark. Vericel also operates a centralized cell manufacturing facility in Ann Arbor, Michigan.

Officers and directors

Robert L. Zerbe M.D. Independent Chairman of the Board
Age: 64
Bio & Compensation  - Reuters
Dominick C. Colangelo President, Chief Executive Officer, Director
Age: 52
Bio & Compensation  - Reuters
Gerard J. Michel Chief Financial Officer, Vice President - Corporate Development
Age: 51
Bio & Compensation  - Reuters
Daniel R. Orlando Chief Operating Officer, Chief Commercial Officer
Age: 49
Bio & Compensation  - Reuters
Ross Tubo Chief Scientific Officer
Age: 55
Bio & Compensation  - Reuters
David Recker M.D. Chief Medical Officer
Age: 57
Bio & Compensation  - Reuters
Steven C. Gilman Ph.D. Director
Age: 62
Bio & Compensation  - Reuters
Heidi Hagen Director
Age: 46
Bio & Compensation  - Reuters
Kevin F. McLaughlin Director
Age: 58
Bio & Compensation  - Reuters
Paul K. Wotton Ph.D. Director
Age: 54
Bio & Compensation  - Reuters